论文部分内容阅读
目的分析新辅助化疗治疗晚期子宫内膜癌疗效。方法收集2012年2月至2013年6月新疆医科大学附属肿瘤医院收治的子宫内膜癌患者74例,随机分为对照组、观察组各37例;对照组采用常规手术治疗,术后辅助放化疗、激素治疗,观察组联合术前辅助化疗。结果新辅助化疗完全缓解2.7%、部分缓解54.1%、稳定40.5%、进展2.7%,缓解56.8%,控制97.3%;观察组术中出血量、手术时间低于对照组,观察组无瘤生存时间(24.4±5.6)个月,高于对照组(20.3±5.1)个月,对照组总有效率54.04%低于观察组75.68%,差异有统计学意义(P<0.05);观察组、对照组生活质量术后明显下降,差异有统计学意义,(P<0.05);两组之间治疗前、化疗后、手术后生活质量比较差异无统计学意义(P>0.05)。结论新辅助化疗治疗晚期子宫内膜癌可增进近期疗效,但可能导致肿瘤进展。
Objective To analyze the effect of neoadjuvant chemotherapy on advanced endometrial cancer. Methods Totally 74 patients with endometrial cancer who were admitted to Cancer Hospital Affiliated to Xinjiang Medical University from February 2012 to June 2013 were randomly divided into control group (n = 37) and observation group (n = 37). The control group received conventional surgery and postoperative adjuvant radiotherapy Chemotherapy, hormone therapy, observation group combined with preoperative adjuvant chemotherapy. Results The neoadjuvant chemotherapy was completely relieved by 2.7%, partially relieved by 54.1%, stabilized by 40.5%, progressed by 2.7%, relieved by 56.8% and controlled by 97.3%. The intraoperative blood loss and operation time in the observation group were lower than those in the control group. (24.4 ± 5.6) months, higher than the control group (20.3 ± 5.1) months. The total effective rate in the control group was 54.04%, which was lower than that in the observation group (75.68%), the difference was statistically significant (P <0.05) The quality of life decreased significantly after operation, with significant difference (P <0.05). There was no significant difference in quality of life between the two groups before and after chemotherapy (P> 0.05). Conclusion Neoadjuvant chemotherapy for advanced endometrial cancer can improve the short-term efficacy, but may lead to tumor progression.